Big pharma has warned Australia to expand its poppy growing industry amid fears of a supply crunch, the FT reports.» Read More
Allergan fell$. 89 or. 7 percent, to $127.76. Baxter International Inc. fell$. 65 or 1.0 percent, to $66.97. Boston Scientific Corp. fell$. 14 or 1.1 percent, to $12.74.
Baxter International Inc. fell$. 65 or 1.0 percent, to $66.97. Bristol-Myers Squibb Co. fell $1.06 or 1.9 percent, to $54.18. Eli Lilly& Co. fell$. 86 or 1.5 percent, to $58.34.
Several insurers, including Molina Healthcare, which administer health plans for California's Medicaid program for the poor are asking states to step in and pay for Gilead Sciences Inc's Sovaldi, a drug that costs $84,000 per patient.
FRANKFURT, Feb 27- Bayer said it would buy privately held Dihon Pharmaceutical Group Co, a maker of traditional herbal Chinese medicines, as the German drugmaker pushes to become the world's largest non-prescription medicines group.
Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee, more than four years after it first filed for approval.
Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee. The company said the drug will be marketed in the United States by Depuy Synthes, a unit of Johnson& Johnson.
NEW YORK/ LONDON, Feb 19- A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck& Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.
NEW YORK, Feb 14- U.S. health regulators have declined to approve proposed wider uses of Bayer AG and Johnson& Johnson's lucrative blood clot preventer Xarelto, the drugmakers said on Friday. An advisory panel to the FDA concluded in January that Xarelto should not be approved to prevent new heart attacks or strokes, a use referred to as secondary prevention.
Feb 14- The U.S. Food and Drug Administration denied an approval to a wider use of Johnson& Johnson's heart drug Xarelto. The blood-clot preventing drug is already approved for use in multiple indications.
Feb 12- U.S. health regulators on Wednesday approved the Johnson& Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer.
Feb 12- U.S. health regulators on Wednesday approved the Johnson& Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer. The Food and Drug Administration decision marks the second approval recently for the medicine, known chemically as ibrutinib.
Feb 11- An advisory panel to the U.S. Food and Drug Administration said on Tuesday that available evidence does not prove that the painkiller naproxen, sold under the brand names Aleve and Naprosyn, carries a lower cardiac risk than rival products.
WASHINGTON, Feb 10- The second-largest revenue source for Puerto Rico last month was an excise tax that has been labeled a "backdoor bailout" for the struggling territory, preliminary estimates released on Monday showed.
NEW YORK, Feb 6- Carlyle Group LP has agreed to buy Illinois Tool Works Inc's industrial packaging unit for $3.2 billion, the private equity firm's latest acquisition of a large unit being carved out of conglomerates.
NEW YORK, Feb 6- nPrivate equity firm Carlyle Group LP is close to reaching an agreement to buy Illinois Tool Works Inc's industrial packaging unit for more than $3 billion, and could announce the deal as soon as Thursday, people familiar with the matter said.
NEW YORK, Feb 6- Illinois Tool Works Inc is nearing a deal to sell its industrial packaging unit for more than $3 billion, with buyout firms Carlyle Group LP and Onex Corp competing in the final stretch of the auction, people familiar with the matter said. It could not be learned, however, if Illinois Tool Works has granted exclusivity to either bidder.
For example, the price discussed for 24 weeks of Sovaldi therapy would run about $2,500 for certain patients at public hospitals, community clinics and non-governmental agencies in India, the Hindu Business Line reported earlier this week.
Feb 4- Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.
The company's shares were down 6 percent at $96.45 on the New York Stock Exchange on Wednesday. "The organic sales decline in personal care was unexpected," BMO Capital Markets analyst Connie Maneaty said.
Jan 28- Johnson& Johnson won an appeal in Louisiana Supreme Court on Tuesday over its marketing of anti-psychotic drug Risperdal as the court overturned a ruling that would have imposed a $258 million penalty on the company.